TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04401982

Intervention type: DRUG
Intervention: Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks
Description: Netarsudil ophthalmic solution 0.02% one drop nightly for 1-2 weeks will be administered
Study: NCT05487092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: Letrozole 2.5mg daily for 6 months

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05241522

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tc-99m-Tilmanocept
Description: Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tc-99m-Tilmanocept
Description: Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Tc-99m-Tilmanocept
Description: Administration of 3 different doses of Tc-99m-Tilmanocept prior to SPECT-CT imaging of the kidney in order to determine the safety and efficacy of tilmanocept imaging for differentiating diabetic kidney disease from other causes of kidney disease.
Study: NCT04571580

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: intracoronary infusion with normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase Injection 9mg
Description: low-dose intracoronary fibrinolytic therapy with reteplase 9mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reteplase Injection 18mg
Description: low-dose intracoronary fibrinolytic therapy with reteplase 18mg
Study: NCT04515342

Intervention type: DIAGNOSTIC_TEST
Intervention: DXA
Description: Each participant will undergo one DXA scan
Study: NCT05237869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blood Flow Restriction Device
Description: Occlusion training involves the application of a cuff to the upper arm that is designed to restrict only the low-pressure blood flow in veins. It does not prevent blood flowing from the heart to the arm.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Physical Therapy
Description: Standard physical therapy protocol for lateral epicondylitis rehab without blood flow restriction.
Study: NCT04515342

Intervention type: OTHER
Intervention: Muscle strength and function assessment
Description: Each patient will have their muscle strength and function assessed with the measurements of handgrip strength, 10 m gait speed and a 30 s sit-to-stand test. They will also fill out a questionnaire assessing Strength, Assistance in walking, Rise from a chair, Climb stairs, and Falls (SARC-F questionnaire).

Intervention type: OTHER
Intervention: Blood samples
Description: Each patient will undergo a physical examination and also deliver blood samples.
Study: NCT04678973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-compassion mindfulness practice
Description: Guided Mindfulness Practice: Participants in the intervention group will receive compassion-based guided meditation audio recordings. Recordings will target self-compassion and body concerns simultaneously.~Psychoeducation: Participants in the intervention group will receive psychoeducation delivered via daily PDF over days 1-6. Psychoeducation will orient users to their upcoming experience, provide education about internalized weight bias, the chronic stress system, the utility of self-compassion practice to regulate physiological and psychological targets, and guidance on establishing, maintaining, and generalizing a mindfulness practice.~Daily prompts: Participants will receive a text message every morning indicating their task for that day.~Weekly prompts: Participants will receive a text message at the end of every week (Days 7, 14, 21, and 28) with a link to a brief adherence survey.
Study: NCT03985358

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Opioid counseling plus standard of care instructions
Description: Same counselor (investigator on the study) will use the same counseling script at the randomization visit as well as at the visit where they come in for pre-admission testing prior to surgery (as a refresher) to counsel patients
Study: NCT05485090

Intervention type: OTHER
Intervention: Questionnaire : Adapted Safety Assessment Scale
Description: Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.

Intervention type: OTHER
Intervention: Questionnaire : Adapted Safety Assessment Scale
Description: Patients caregivers will complete the questionnaire twice : once at enrollment, then 3 to 10 days after enrollment.
Study: NCT05980494

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal Saline
Description: normal saline cyrstalloids infusion with rate of 4ml/kg /h for 3 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lung ultrasound
Description: Lung ultrasound by Philips clear vue350, Philips healthcare, Andover MAO1810, USA, Machine ID:1385 will scan For each hemi-thorax 3 main areas (anterior (Ant), lateral (Lt) and posterior (Post)) marked by the para-sternal, anterior axillary and posterior axillary lines for a total of 28 sectors will be identified

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inferior vena cava measurements
Description: The inferior vena cava was explored in the subxiphoid window in its sagittal view-just below the junction between the inferior vena cava and suprahepatic veins which lie approximately 0.5 to 3 cm from the right atrium, following the American Society of Echocardiography guidelines.; The (IVC distensibility index (dIVC) was calculated as (maximum diameter - minimum diameter)/minimum diameter.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: passive leg raising test (PLRT)
Description: Regardless of CVP (i.e., during blind PLR), noninvasiveΔPLR systolic arterial pressure (SAP) more than 17% reliably identify fluid responders. During CVP-guided PLR, in case of sufficient change in CVP (at least of 2 mmHg), noninvasiveΔPLR SAP perform better (cutoff of 9%). These findings, in sedated patients who had already undergone volume expansion and/or catecholamines, have to be verified during the early phase of circulatory failure (before an arterial line).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pulse pressure variation
Description: patients will be temporarily sedated and paralyzed and on fully controlled mechanical ventilation. No spontaneous breathing effort will be detected on the mechanical ventilator waveform monitor ensuring that the respiratory changes in arterial pressure reflected only the effects of positive pressure ventilation. Modes of ventilation is selected to volume or pressure controlled ventilation, depending on the decision of the primary physicians. A tidal volume will be not less than 8 ml/ kg (predicted body weight). The preset respiratory rate will be at 14 breath/min. Positive end expiratory pressure (PEEP) will be between 8 and 10 cmH2O. The plateau pressure was kept at below 30 cmH2O. In all patients, radial artery cannulation will be done for invasive blood pressure monitoring (using a 20 G cannula), PPV is calculated directly on Nihon Kohden monitores at base line.
Study: NCT06091306

Intervention type: BEHAVIORAL
Intervention: Psychotherapy
Description: Multifamily therapy (MFT), which involves bringing several families together to address the problem of anorexia nervosa, has proved effective for several years now.~Since January 2019, multifamily therapy has been offered to adolescents aged 12 to 18 who are being treated for anorexia nervosa at the Maison de Solenn-Maison des Adolescents at Cochin Hospital, and to their families.~Each group brings together 5 to 7 families and comprises 10 3-hour sessions, with 3 weeks between each session. 2 groups are offered per year. Multifamily therapy therefore involves 10 to 14 families per year. It complements the other approaches available in the department.
Study: NCT06295822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nuan-gong-ye
Description: In this study, the ingredients of nuan-gong-ye are myrrh, dragon's blood, yanhu tuber, white mustard seed, asarum root, argy wormwood leaf, holly oil, clove oil, cinnamon bark oil, glycerin, PEG400.
Study: NCT05518526

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Annamycin (L-Annamycin)
Description: Study drug consists of L-Annamycin as a lyophilised powder in 50-mL single-use vials containing 45 mg of L-Annamycin must be reconstituted with 45 mL of 0.9% sodium chloride injection between 34 to 42℃, USP, and then diluted 1:1 with 0.9% sodium chloride injection between 34 to 42℃ in non-polyvinyl chloride IV bags before intravenous infusion. The dose of L-Annamycin will be intravenously applied during 2 hours infusion on D1, D8, and D15 of each 28-day cycle (up to Cycle 6th).
Study: NCT04805008

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lactation cookies
Description: 1 serving of 2 OZ of cookies per day for 30 consecutive days. These cookies will contain ingredients thought to increase breast milk production.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control cookies
Description: 1 serving of 2 OZ of cookies per day for 30 consecutive days.~The cookies will not contain ingredients thought to increase breast milk production.
Study: NCT06243120

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine IV
Description: The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine IV
Description: The study group will receive lidocaine (2%) 1mg/ kg iv diluted by normal saline to a volume of 100 ml. The VAS will be assessed every 10 minutes for 60minutes after the treatment. A regression of more than 4 points of VAS score is considered a success and if less than 4 points , it will be considered as a failure.
Study: NCT05620784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: 20mg of IV furosemide injection during the morcellation phase of HoLEP
Study: NCT02478450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage
Study: NCT06259435

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-energy dense diet
Description: Subjects will follow time-restricted eating of a low energy dense diet
Study: NCT02478450

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Q-Cells
Description: cellular therapeutic comprised of human cells of the glial lineage
Study: NCT06295822

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo was 1/20 concentration of nuan-gong-ye plus glycerin and PEG400.
Study: NCT05876247

Intervention type: OTHER
Intervention: Electromagnetic Articulography
Description: Motion tracking sensors will track articulatory movements of the tongue, jaw and lips

Intervention type: OTHER
Intervention: Electromagnetic Articulography
Description: Motion tracking sensors will track articulatory movements of the tongue, jaw and lips
Study: NCT05466630

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Serological field test for HAT
Description: Whole blood is tested by lateral flow or agglutination (CATT) for the presence of trypanosome specific antibody. Participants testing positive for at least one of these tests will undergo microscopic examination to detect trypanosomes (lymph, mAECT on blood) and DBS will be prepared for immunological and molecular laboratory testing.
Study: NCT04465240

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Virtual reality
Description: Participants are immersed in a neighborhood environment in virtual reality

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality
Description: Participants are immersed in a neighborhood environment in virtual reality
Study: NCT05671029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir and moxifloxacin placebo
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir placebo, moxifloxacin and moxifloxacin placebo
Description: oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pritelivir placebo, moxifloxacin placebo and moxifloxacin
Description: oral administration
Study: NCT06075251

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I-InTERACT-North
Description: I-InTERACT-North is a virtual stepped-care positive parenting program. It comprises online psychoeducational modules as well as live therapy and coaching sessions. The program lasts anywhere from 1 to 16 weeks depending on parents' progress.
Study: NCT05476094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene Phosphatidylcholine
Description: AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyene Phosphatidylcholine
Description: AYP-101 1 - 25 mg of essential phospholipids in 1 mL AYP-101 2 - 50 mg of essential phospholipids in 1 mL Placebo - Essential phospholipids in 1 mL 00 mg
Study: NCT04626232

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: N-SLEEVE technique
Description: The N-SLEEVE technique (figure 2) consists of creating a gastric total fundoplication (Nissen technique) before to perform the removal of 2/3 of the stomach (SLEEVE technique).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: SLEEVE
Description: SLEEVE Technique : Removal of 2/3 of the stomach
Study: NCT05059977

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive subcutaneous infusion of TAK-881 on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive subcutaneous infusion of TAK-881 on Day 1.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-881
Description: Participants will receive subcutaneous infusion of TAK-881 on Day 1.
Study: NCT05674110

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DSMES Intervention
Description: This study will provide participants with on-line education, plus weekly text messaging that will contain messages of support or encouragement sent to participants in the individual's preferred language (English or Spanish). Participants will be encouraged to attend monthly group support meetings to review the content and address any questions. Group meetings will occur at 3-time intervals (end of months: 1, 2, and 3). Group support meetings will be held in-person at a food pantry and moderated by peer mentors, nursing students, registered dietitian nutritionist (RDN), and/or a diabetes care and education specialist (DCES). Group support meetings will be held in Spanish and/or English, with no more than 10 participants in a group at one time, and will last approximately 50 minutes. For the duration of the study, participants will continue to receive monthly food items from the food pantry.
Study: NCT05466630

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: malaria rapid test
Description: RDT detecting HRP2 plasmodium antigen.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Immunologic laboratory tests
Description: Laboratory tests detecting trypanosoma brucei gambiense specific (VSG) antibodies in DBS. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Molecular laboratory tests
Description: Laboratory tests detecting Trypanozoon specific nucleic acids. These tests will only be carried out on participants that are positive in at least on of the rapid serological tests
Study: NCT04588207

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea
Description: Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea
Description: Groups On Urea, Then Off Urea and Off Urea, Then On Urea will receive urea during period 1 and period 2 of the study, respectively. The investigators will use the new American formulation of oral urea (i.e., Ure-Na™), which is packaged as a powder and mixed with 4 ounces. of water for oral consumption. Urea will be started at a dose of 15 grams of urea per mouth once daily. Dose titration will be based on the absolute increase in PNa on days 7 and 14. The urea dosing scheme will involve increasing from the starting dose of 15 grams/day to 30 grams/day (in 2 divided doses) based on the change in and absolute value of PNa, and subsequently, from 30 grams/day to 60 grams/day (in 2 divided doses) when indicated. The maximal dose of urea administered will be 60 g/day.
Study: NCT05924113

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Latin Dance
Description: Latin dance sessions that include a warm-up routine with music, two choreographed dances, and a cooldown routine with music.
Study: NCT04816383

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding at AU Apple-Based Smartphone Application
Description: This is a free Apple-Based Smartphone Application the participant can download. In the application, there is information and tips for breastfeeding success and continuation, as well as information on additional resources both online and in the community as a whole.
Study: NCT04838704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib+Calcineurin +Methotrexate
Description: low-dose ruxolitinib combine with calcineurin and short course of methotrexate.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcineurin +Methotrexate+Mycophenolate mofetil
Description: calcineurin and short course of methotrexate and mycophenolate mofetil
Study: NCT05407961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3532226
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered SC.
Study: NCT06272526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internet Based Intervention - GUIDED
Description: The experimental group participants will be in treatment through web-based intervention consisting of five to seven weeks. The intervention program will be offered to participants through the website https://kendikendineyardim.org, the online self-help platform in Turkey. Participants will be able to use the system with their e-mail addresses and passwords.The intervention consists of five modules consisting of behavioral, emotional and cognitive content. The modules include text, interactive forms, animated videos, audio recordings, and images. Participants in this arm will receive weekly feedback from guides via the platform's message sending feature.
Study: NCT05407961

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Administered SC.
Study: NCT06488963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NatraCure Cold Therapy gloves and socks
Description: These gloves and socks will be adjusted and tied to the child's wrists and ankles. There are sizes suitable for all ages and the dimensions of the gloves and socks can be adjusted with a snap fastener. The gloves and socks contain a soft Lycra lining and four inner gel cold packs to ensure full length cold therapy treatments. When the children wear these gloves and socks, they can still move their fingers and toes easily. In addition, it is a great advantage that the iced gel packs do not touch the child's skin directly.
Study: NCT04964154

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protect Your Elders Campaign
Description: This is a behavioral intervention where participants will receive cultural appropriate educational information about COVID-19 testing and vaccination.
Study: NCT06243887

Intervention type: OTHER
Group type: OTHER
Intervention: Enhanced Recovery After Surgery (ERAS) protocol in minimal invasive esophagectomy
Description: Enhanced Recovery After Surgery (ERAS) refers to patient-centered, evidence-based, multidisciplinary team developed pathways for a surgical specialty and facility culture to reduce the patient's surgical stress response, optimize their physiologic function, and facilitate recovery.

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care approaches in minimal invasive esophagectomy
Description: standard of care approaches other than ERAS
Study: NCT05950789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality application
Description: During the preparation stage of the port catheter injection attempt, the intervention group was given a calming video and music concert using virtual reality glasses.~With virtual reality glasses, patients watch three-dimensional video nature images, which we determined according to the patient's preference, accompanied by music. They put on the virtual reality glasses before the process started and removed them after the process was over.